NASDAQ$PRCT
PROCEPT BioRobotics Corporation · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021.
PROCEPT BioRobotics reported Q4 2021 revenue of $10.1 million, a significant increase from $3.2 million in the same period of 2020. The growth was primarily driven by system sales to new hospital customers and increased utilization among existing customers. The company's gross margin also improved substantially, reaching 44.5% compared to 14.6% in the prior year period.
- Revenue of $10.1 million for the fourth quarter of 2021, compared to $3.2 million from the same period of 2020
- U.S. system and rental revenue of $5.0 million for the fourth quarter of 2021, compared to $1.2 million in the prior year period
- U.S. handpiece and consumables revenue of $3.4 million for the fourth quarter of 2021, compared to $0.8 million in the prior year period
- Gross margin for the fourth quarter 2021 was 44.5% compared to 14.6% in the prior year period
Headline financials
Revenue & EPS history
PROCEPT BioRobotics · Revenue · Quarterly
$10.1M
Revenue by segment
PROCEPT BioRobotics · $9.69M total across 4 segments · Q4 2021
- U.S. System Sales$5.01M+307.4%51.7%
- U.S. Consumables$3.44M+346.7%35.5%
- Intl. System Sales$768K+7.6%7.9%
- Intl. Consumables$475K+7.2%4.9%
Forward guidance
The Company projects revenue for the first quarter of 2022 to be in the range of $12.0 million to $12.5 million and full year 2022 revenue to be in the range of $54.0 million to $58.0 million and gross margin to be in the range of 47.0% to 49.0%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.3%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+0.6%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+40.6%
Q3 2024
Best reaction
-15.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.7% | +16.0% | +21.3% | |
| Q4 2025 | -15.2% | -5.7% | -5.3% | |
| Q3 2025 | +1.6% | -7.5% | +2.7% | |
| Q1 2025 | -5.6% | +1.1% | +3.0% | |
| Q4 2024 | +8.6% | -3.4% | -4.2% | |
| Q3 2024 | +40.6% | +34.2% | +41.5% | |
| Q2 2024 | -9.4% | -4.3% | +24.8% | |
| Q1 2024 | +16.5% | +15.9% | +25.3% | |
| Q4 2023 | +1.1% | +0.5% | +1.2% | |
| Q3 2023 | +21.7% | +22.5% | +39.5% | |
| Q2 2023 | -6.7% | -10.3% | -18.4% | |
| Q1 2023 | -15.0% | -20.1% | -10.9% | |
| Q4 2022 | +1.2% | -4.3% | -28.7% | |
| Q3 2022 | -9.9% | -8.4% | +5.8% | |
| Q2 2022 | +4.3% | +4.3% | +0.2% | |
| Q1 2022 | -5.1% | -17.9% | +19.5% | |
| Q4 2021 | +1.2% | +5.9% | +38.7% | |
| Q3 2020 | -2.2% | -4.5% | -28.0% | |
| Q4 2020 | -2.2% | -4.5% | -28.0% | |
| Q2 2021 | -2.2% | -4.5% | -28.0% | |
| Q1 2021 | -2.2% | -4.5% | -28.0% | |
| Q3 2021 | -4.4% | -3.9% | -29.6% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro